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ABSTRACT
sually, prolactin circulates in three major 
molecular forms in blood, viz: monomeric Uprolactin (little prolactin), dimeric prolactin 
(big-prolactin), and polymeric prolactin (big-big 
1,2
prolactin or macroprolactin).  The molecular weights 
of these circulating forms of prolactin are 23kDa, 48-
3
56kDa and 150-170kDa respectively.  In health, 
monomeric prolactin is the major circulating form and 
constitutes 80 to 90% of circulating prolactin while big-
prolactin and macroprolactin constitute 20% and less 
3 
than 1% respectively. Hyperprolactinaemia is a fairly 
common endocrine abnormality among women of 
4
child-bearing age.  Most cases of hyperprolactinaemia 
are due mainly to elevated plasma concentrations of 
monomeric prolactin. However, some cases of 
hyperprolactinaemia occur as a result of increased 
plasma levels of macroprolactin. This has been referred 
5
to as macroprolactinaemia.  Macroprolactin mostly 
consists of a heteropolymeric complex of monomeric 
6prolactin and immoglobulin G (IgG).  It exerts little or 
7
no biological action of monomeric prolactin in vivo.  
Consequently, premenopausal female patients with 
macroprolactinaemia may or may not present with 
clinical features of hyperprolactinaemic syndrome. 
Hence, macroprolactinaemia was suggested as a cause 
8
of pseudohyperprolactinaemia.  Macroprolactinaemia 
has been reported as a cause of frequent misdiagnosis, 
unnecessary investigation, and inappropriate 
treatment of hyperprolactinaemia especially in women 
9
of child-bearing age.  In the routine clinical laboratory 
setting, the presence of macroprolactinaemia is 
commonly screened using the polyethyleneglycol 
10,11
precipitation method.
In this report, we present a case of 33-year old nullipara 
who presented with constant frontal headache and 
severe hyperprolactinaemia but had regular menstrual 
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first testing gave a serum prolactin value of 76.2ng/ml 
( 8 . 3 9 –  2 0 . 1 5 ) .  D e s p i t e  t h e  p e r s i s t e n t  
hyperprolactinaemia the patient continuously had 
regular menstrual cycles and she admitted to 
experiencing the presumptive symptoms of ovulation. 
To rule out structural and functional disorders of the 
hypothalamic-pituitary endocrine axis, patient had a 
brain CT scanning. The tomographic technique 
comprised a scanogram followed by 3mm pre- and 
post-intravenous contrast helical sections with coronal 
and sagittal reformations. The findings were as follows: 
normal cerebral and cerebellar hemispheres; normal 
sulci and gyri; normal grey-white matter interphase; no 
intraxial or extraaxial mass lisions or collection seen; 
and normal ventricular systems. The radiological 
diagnosis was a normal brain CT scan.
Subsequently, the patient was treated with oral 
bromocripstine 2.5mg twice daily for 1 month. 
Following the completion of the bromocriptine 
treatment, a follow-up serum prolactin estimation 
revealed a value of 60ng/ml (2 - 29). Consequent upon 
the above laboratory and radiological findings, a 
provisional diagnosis of hyperprolactinaemia 
secondary to macroprolactinaemia was suggested. 
Based on this a serum sample was collected from the 
patient for macroprolactin screening using the 
polyethyleneglycol precipitation test. The test revealed 
a recovery (%) of less than 40% for monomeric 
prolactin. This was strongly suggestive of 
macroprolactinaemia and when combined with lack of 
features of hypogonadotropichypogonadism in the 
presence of severe hyperprolactinaemia, a diagnosis of 
macroprolactinaemia was made.
cycles and no galactorrhea. Serial laboratory and 
radiological investigations excluded tumours of the 
hypothalamic-pituitary axis. Laboratory screening for 
macroprolactin revealed serum prolactin recovery of ≤
40% which strongly suggestedmacroprolactinaemia.
CASE REPORT
The patient is a 33-year old nullipara who presented 
with history of dysmenorrhea and monthly cyclic 
headache that was mostly frontal in location. While the 
symptoms prevailed, her menstrual cycle remained 
regular with normal flow. There was no associated 
history of spontaneous or expressible galactorrhea. The 
patient was not on any routine drug that can increase 
plasma prolactin concentration. For the symptoms, 
patient was referred to the gynaecology clinic of 
University of Calabar Teaching Hospital for further 
investigation and management. The patient was 
c l in ica l ly  evaluated and some laboratory  
investigations were carried out. A baseline 21-day 
fertility hormone profile testing was performed and the 
following results were obtained: luteinizing hormone 
(LH) = 7.5ìIU/ml (5 - 20); follicle stimulating hormone 
(FSH) = 5.0ìIU/ml (<20); progesterone (PROG) = 
11.0ng/ml (2.5 - 32); estradiol (E2) = 66.0ng/ml (60 - 
150); prolactin (PRL) = 80.0ng/ml (8.39 – 20.15). The 
laboratory test result revealed hyperprolactinaemia 
despite normal levels of gonadotropins and gonadal 
hormones. In addition, serum TSH estimation carried 
out concomitantly with the fertility hormone profile 
revealed euthyroidism. The patient is a nun and there 
were no history of exercise, sexual activity or breast 
stimulation prior to blood specimen collection.
A repeat serum PRL estimation two weeks after the 
Table 1: Patient's day-21 fertility hormone profile
Hormone  Serum concentration  Reference interval
LH (ìIU/mL)
 




























TSH (mIU/L) 2.6 0.2 – 5.0
Table 2: Patient's serial serum prolactin concentrations and percent monomeric PRL recovery
Date  25/09/10  09/10/10  3/4/11
Serum PRL (ng/mL)  80.0  76.2  60.0
% monomeric PRL Recovery (%R)
 
%R = Serum PRL in supernatant
 
x 100%
          Serum PRL before PEG precipitation
 = 16.9    x 100%  
    60.0  
= 28.2%
NB: Macroprolactinaemia is conventionally defined by % monomeric PRL recovery 
10,11
=40% .
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regular ovulatory menstrual cycles in the presence of 
severe hyperprolactinaemia. Expectedly, at this level of 
h y p e r p r o l a c t i n a e m i a  t h e  s y m p t o m s  o f  
hyperprolactinaemia such as amenorrhea and 
galactorrhea would be present in the patient. However, 
the patient only had dysmenorrhea with cyclic frontal 
headache, which prompted the clinical, laboratory, and 
radiological evaluations. To further consolidate the 
diagnosis of macroprolactinaemia in this patient, brain 
CT scan result was normal, suggesting the absence 
pituitary adenoma.
Macroprolactinaemia has been recognized as a 
frequent cause of misleading diagnosis, unnecessary 
investigation, and wrong treatment of affected 
9
patients.  Our reported case was subjected to series of 
not-so-cheap investigations and treatment and yet the 
hyperprolactinaemia persisted. It has been emphasized 
that clinicians should be aware of the macroprolactin 
3
problem.  Normal ovulatory cycles in the presence of 
sustained hyperprolactinaemia among premenopausal 
w o m e n  s h o u l d  r a i s e  a  s u s p i c i o n  o f  
18
macroprolactinaemia.  The ability to recognize this 
will save the patient the burden of unnecessary 
investigations and treatment which may not be cost-
effective after all. Usually, a high-index of suspicion 
should be entertained. This should be followed by 
screening for macroprolactinaemia using the 
polyethyleneglycol precipitation method. This 
screening test has been extensively validated and 
adapted by most clinical laboratories in developed 
10,11
countries.  It is also inexpensive, easy to carry out 
and amenable to routine laboratory application. Where 
available, the presence of macroprolactin should be 
confirmed using gel-filtration chromatographic (GFC) 
method for macroprolactin detection. The GFC method 
is the gold-standard and confirmatory test for 
macroprolactin detection.19For our reported case, we 
were not able to carry out the GFC test due to 
unavailability and cost of the test procedure. 
In most studies, macroprolactin screening were carried 
out for patients with persistent serum prolactin 
concentration that was above 700mIU/L (or 
3 , 9 , 1 0
20ng/ml). Notwithstanding, screening for 
macroprlactinaemia has been recommended for all 
cases of biochemical hyperprolactinaemia with or 




This report has shown that macroprolactinaemia is a 
potential  cause of  hyperprolactinaemia in 
premenousal Nigerian women. Macroprolactin is a 
heterpolymeric complex of monomeric PRL and IgG 
with little or no biological activity. Its presence should 
be suspected and investigated in premenopausal 
DISCUSSION
The  case  repor t  has  fur ther  h igh l ighted  
macroprolactinaemia as an important but seldom 
recognized cause of biochemical hyperprolactinaemia 
a m o n g  w o m e n  o f  c h i l d b e a r i n g  a g e .  
Macroprolactinaemia causes raised serum prolactin 
concentration without, in most cases, accompanying 
3
symptoms of the hyperprolactinaemic syndrome.  The 
presence of high levels of macroprolactin in blood can 
cause a diagnostic and management confusion with 
5,8,9
regards to hyperprolactinaemia.
Prolactin is a 199-aminoacid protein hormone that is 
synthesized and secreted by the lactotrophic cells of the 
1
anterior pituitary gland.  It circulates in plasma in three 
molecular forms viz: monomeric PRL, big PRL and 
2,7
macro PRL.  Prolactin seems to play a permissive role 
in the regulation of reproduction. Normal levels of 
serum prolactin is a necessity for normal reproductive 
12
function in premenopausal females.  Commonly, 
i n c r e a s e d  c i r c u l a t i n g  l e v e l  o f  p r o l a c t i n  
(hyperprolactinaemia) is associated with inhibition of 
synthesis and release of gonadotrophin-releasing 
13
hormone (GnRH) from the hypothalamus.  Thus, 
hyperprolactinaemia is a notable cause of 
hypogonadotropichypogonadism which is often 
characterized by oligomenorrhea/ amenorrhea; 
oligoovulation/anovulation and infertility among 
14
women of child-bearing age.
Generally, the causes of hyperprolactinaemia may be 
4
physiological ,  pathological  or  idiopathic .  
Physiological hyperprolactinaemia occurs in 
p r e g n a n c y  a n d  l a c t a t i o n .  P a t h o l o g i c a l  
hyperprolactinaemia can be caused by pituitary 
tumours, drugs, polycystic ovary syndrome, and 
4
hypothyroidism.  Recently, macroprolactinaemia was 
recognized as a fairly common cause of biochemical 
5,8
hyperprolactinaemia.  Macroprolactin has been 
shown to have little or no biological activity in in vitro 
15
bioassay studies.  Thus, women with biochemical 
hyperprolactinaemia due to macroprolactinaemia may 
present with just few or no clinical features of the 
3,7
hyperprolactinaemic syndrome.  Several reasons 
have been suggested on the relative biological 
inactivity of macroprolactin in vivo. The most plausible 
is the high-molecular weight nature of macroprolactin 
which prevents its interaction with cell-surface 
6,7
prolactin receptors.  Macroprolactin mostly consists 
of a heteropolymeric complex of monomeric prolactin 
7,16
with IgG.  It is also possible that the IgG that is avidly 
bound to prolactin are circulating anti-prolactin 
autoantibodies which are predominantly inhibitory in 
17
action.
For our reported case, the patient persistently had 
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w o m e n  w i t h  s u s t a i n e d  b i o c h e m i c a l  
hyperprolactinaemia in the presence of normal regular 
ovulatory cycles.  The t imely detection of  
macroprolactin and diagnosis of macroprolactinaemia 
will avert diagnostic confusion and save affected 
patients from misleading diagnosis, inappropriate 
investigations, and unnecessary treatment.
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